Redhill Biopharma (RDHL): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
1 concentrated manager holds it with a median weight of 0.0%.
Who owns Redhill Biopharma?
Redhill Biopharma trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Alumni Capital, 10.0% (13G filed Oct 20, 2025) and Ya Ii Pn, 9.9% (13G filed Dec 23, 2025). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Yorkville Advisors Global (122,131 ADRs), Gagnon Securities (88,405 ADRs) and Citadel Advisors (65,321 ADRs).
Which institutions hold the most Redhill Biopharma shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Yorkville Advisors Global: 122,131 ADRs
- 2. Gagnon Securities: 88,405 ADRs
- 3. Citadel Advisors: 65,321 ADRs
- 4. Rhumbline Advisers: 13,755 ADRs
- 5. Lido Advisors: 11,009 ADRs
- 6. GAMMA Investing: 6,957 ADRs
- 7. Citigroup: 4,378 ADRs
- 8. Federation des caisses Desjardins du Quebec: 3,388 ADRs
- 9. UBS Group: 100 ADRs
- 10. SBI Securities: 15 ADRs
Sources:13G by Alumni Capital (Oct 20, 2025) ↗13G by YA II PN (Dec 23, 2025) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Redhill Biopharma revenue
Redhill Biopharma reported annual revenue of $8.0 million for fiscal year 2024 (year ended December 31, 2024), according to its Form 20-F filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Change in managers (1 → 1): 0 opened · 0 exited = 0
Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- Gagnon Securities$74.7K0.0%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of RDHL (all 13F filers)
- Yorkville Advisors Global122 KType not verified−229 K
- Gagnon Securitiesconcentrated88 KType not verified0
- Citadel Advisors65 KQuant or multi-manager+45 K
- Rhumbline Advisers14 KIndex manager+8,639
- Lido Advisors11 KWealth adviser+11 K
- GAMMA Investing6,957Type not verified+273
- Citigroup4,378Bank or trading desk+4,378
- Federation des caisses Desjardins du Quebec3,388Bank or trading desk0
- UBS Group100Bank or trading desk−726
- SBI Securities15Type not verified+11
- Yorkville Advisors Global
- Shares
- 122 K
- Change
- −229 K
See more
- Type
- Type not verified
- Value
- $107K
- Gagnon Securitiesconcentrated
- Shares
- 88 K
- Change
- 0
See more
- Type
- Type not verified
- Value
- $74.7K
- Shares
- 65 K
- Change
- +45 K
See more
- Type
- Quant or multi-manager
- Value
- $55.2K
- Shares
- 14 K
- Change
- +8,639
See more
- Type
- Index manager
- Value
- $11.6K
- Shares
- 11 K
- Change
- +11 K
See more
- Type
- Wealth adviser
- Value
- $9.3K
- Shares
- 6,957
- Change
- +273
See more
- Type
- Type not verified
- Value
- $5.9K
- Shares
- 4,378
- Change
- +4,378
See more
- Type
- Bank or trading desk
- Value
- $3.7K
- Shares
- 3,388
- Change
- 0
See more
- Type
- Bank or trading desk
- Value
- $2.9K
- Shares
- 100
- Change
- −726
See more
- Type
- Bank or trading desk
- Value
- $85
- Shares
- 15
- Change
- +11
See more
- Type
- Type not verified
- Value
- $13
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers